Sogroya Side Effects
Generic name: somapacitan-beco
Medically reviewed by Drugs.com. Last updated on May 14, 2023.
Note: This document contains side effect information about somapacitan-beco. Some dosage forms listed on this page may not apply to the brand name Sogroya.
Applies to somapacitan-beco: subcutaneous solution.
Elevated phosphate and creatine phosphokinase occurred intermittently and were non-progressive.[Ref]
Very common (10% or more): Elevated phosphate (17.5%)
Common (1% to 10%): Elevated creatine phosphokinase, blood creatinine kinase increase, weight increased
Frequency not reported: Glucose intolerance, diabetes mellitus, fluid retention[Ref]
Common (1% to 10%): Sleep disorder, dizziness
Frequency not reported: Intracranial hypertension[Ref]
Common (1% to 10%): Adrenal insufficiency, hypoadrenalism, hypothyroidism[Ref]
Common (1% to 10%): Dyspepsia, vomiting
Frequency not reported: Pancreatitis[Ref]
Frequency not reported: Severe hypersensitivity[Ref]
Very common (10% or more): Back pain (10%)
Common (1% to 10%): Arthralgia[Ref]
Common (1% to 10%): Anemia[Ref]
Frequency not reported: Neoplasms[Ref]
Common (1% to 10%): Peripheral edema
Frequency not reported: Increased mortality in patients with acute critical illness[Ref]
Common (1% to 10%): Hypertension[Ref]
Frequency not reported: Lipohypertrophy, lipoatrophy[Ref]
Common (1% to 10%): Tonsillitis[Ref]
More about Sogroya (somapacitan-beco)
- Check interactions
- Compare alternatives
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: growth hormones
Related treatment guides
1. "Product Information. Sogroya (somapacitan)." Novo Nordisk Pharmaceuticals Inc (2020):
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.